Lupin Drug Recall! Did Your Medication Make the USFDA’s List of 3552?

Lupin’s share price rose by up to 1.5 percent, reaching a high of Rs 1,585.8 on the NSE during morning trading, breaking a nine-day losing streak.

This increase came on Monday, June 24, following the Mumbai-based pharmaceutical company’s announcement that it received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Somerset, New Jersey manufacturing facility, with a Voluntary Action Indicated (VAI) status.

Lupin shares rose by up to 1.5 percent to reach a high of Rs 1,585.8 on the NSE during morning trading, ending a nine-day losing streak. The inspection of the facility took place from May 7 to May 17, 2024.

“We are very pleased to have received the EIR with a satisfactory VAI status for our Somerset facility. This is a significant milestone in building our reputation of being best-in-class in Quality and Compliance,” said Nilesh Gupta, Managing Director of Lupin, in a regulatory filing dated June 22.

Additionally, Lupin and a unit of Aurobindo Pharma are recalling products from the American market due to manufacturing issues, according to the US health regulator.

According to the latest Enforcement Report from the US Food and Drug Administration (USFDA), a US-based unit of Lupin is recalling a medication used to treat bacterial infections.

Lupin is a Mumbai-based pharmaceutical company that develops and markets a diverse range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company operates in over 100 markets, including the U.S., India, South Africa, the Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.